ArticleEndocrine2025
Experience with apheretic treatment in the chronic management of severe hypertriglyceridemia: case series.
Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimChylomicronemia Syndrome (CS) refers to a group of lipid disorders characterized by the accumulation of chylomicrons in the plasma due to impaired lipolytic clearance. It encompasses various clinical features, including Familial Chylomicronemia Syndrome (FCS) and Multifactorial Chylomicronemia Syndrome (MCS). Diagnosing CS is a significant clinical challenge, as it is essential for identifying patients at highest risk of acute pancreatitis, preventing recurrence, and improving cardiovascular outcomes. Methods and Case Descriptions. Since 2008, we have identified eight patients residing in the same geographical area of Central Italy (Tuscany Region), all referred to us for severe and treatment-resistant hypertriglyceridemia. During this time, new therapeutic agents such as volanesorsen and lomitapide became available. However, none of these patients met the reimbursement criteria set by the Italian Medicines Agency (AIFA). We describe the clinical management and follow-up of these patients, in whom plasma and lipoprotein apheresis remain an effective therapy for reducing the risk of pancreatitis.
Indexed as
Identifiers
40587026What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.